Mcl-1 Cancer Research Results

Mcl-1, myeloid cell leukemia 1: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
A member of the Bcl-2 family of proteins, which play a crucial role in regulating apoptosis, or programmed cell death. In cancer, Mcl-1 is often overexpressed, contributing to the development and progression of various types of tumors.
Mcl-1 is often overexpressed in several cancers, including hematological malignancies (like leukemia and lymphoma) and solid tumors (such as breast, lung, and prostate cancers).
Mcl-1 inhibits apoptosis by binding to pro-apoptotic proteins, preventing them from triggering the cell death pathway.


Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, ChemoSen↑,
152- CUR,    Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer
- in-vivo, Pca, NA
β-catenin/ZEB1↓, AR↓, STAT3↓, p‑Akt↓, Mcl-1↓, Bcl-xL↓, cl‑PARP↑, miR-21↓, miR-205↑, TumCG↓, TumCP↓, TumCI↓, angioG↓, TumMeta↓,
161- CUR,  MeSA,    Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK
- in-vitro, BC, MDA-MB-231 - in-vitro, Pca, DU145
Mcl-1↑, Mcl-1↓, MPT↑, AIF↑, chemoPv↑, Apoptosis↑, ROS↑, FAK↓, STAT3↓, NF-kB↓,
76- QC,    Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy
- in-vitro, Pca, PC3
aSmase↝, Diablo↑, Fas↓, Hsc70↓, Hif1a↓, Mcl-1↓, HSP90↓, FLT4↓, EphB4↓, DNA-PK↓, PARP1↓, ATM↓, XIAP↝, PLC↓, GnT-V↝, heparanase↝, NM23↑, CSR1↑, SPP1↓, DNMT1↓, HDAC4↓, CXCR4↓, β-catenin/ZEB1↓, FBXW7↝, AMACR↓, cycD1/CCND1↓, IGF-1R↓, IMPDH1↓, IMPDH2↓, HEC1↓, NHE1↓, NOS2↓,
881- RES,    Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein
- in-vitro, BC, MDA-MB-231 - in-vitro, PC, PANC1 - in-vitro, Pca, DU145
TumCCA↑, cycD1/CCND1↓, Bcl-xL↓, Mcl-1↓, other↓,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   MEK↓, 1,   MMP↓, 1,   MPT↑, 1,   XIAP↝, 1,  

Core Metabolism/Glycolysis ⓘ

AMACR↓, 1,   PI3K/Akt↓, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 1,   aSmase↝, 1,   Bak↑, 1,   BAX↑, 2,   Bcl-2↓, 2,   Bcl-xL↓, 4,   BID↑, 1,   BIM↑, 1,   Casp3↑, 1,   Casp9↑, 1,   CSR1↑, 1,   Diablo↑, 1,   DR4↑, 1,   DR5↑, 1,   Fas↓, 1,   Mcl-1↓, 6,   Mcl-1↑, 1,   NOXA↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   RTK-RAS↓, 1,  

Transcription & Epigenetics ⓘ

miR-205↑, 1,   miR-21↓, 1,   other↓, 1,   SPP1↓, 1,  

Protein Folding & ER Stress ⓘ

Hsc70↓, 1,   HSP90↓, 1,  

DNA Damage & Repair ⓘ

ATM↓, 1,   DNA-PK↓, 1,   DNMT1↓, 1,   P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 1,   PARP1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   cycD1/CCND1↓, 2,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   FBXW7↝, 1,   FOXO3↑, 1,   HDAC4↓, 1,   IGF-1R↓, 1,   PI3K↓, 1,   STAT3↓, 2,   TumCG↓, 2,  

Migration ⓘ

EphB4↓, 1,   FAK↓, 1,   GnT-V↝, 1,   heparanase↝, 1,   NM23↑, 1,   TumCI↓, 1,   TumCP↓, 2,   TumMeta↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 1,   FLT4↓, 1,   Hif1a↓, 1,  

Barriers & Transport ⓘ

NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CXCR4↓, 1,   NF-kB↓, 3,  

Cellular Microenvironment ⓘ

PLC↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↓, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 1,   HEC1↓, 1,   HER2/EBBR2↓, 1,   NOS2↓, 1,  

Functional Outcomes ⓘ

chemoPv↑, 1,   IMPDH1↓, 1,   IMPDH2↓, 1,  
Total Targets: 84

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Mcl-1, myeloid cell leukemia 1
3 Curcumin
1 Docetaxel
1 methylseleninic acid
1 Quercetin
1 Resveratrol
1 Sulforaphane (mainly Broccoli)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:182  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page